Cannabis Law Report
JULY 27, 2021
The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.
Cannabis Law Report
JANUARY 20, 2022
ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Founded in 2013, Eleusis is dedicated to transforming psychedelics into medicines. About Eleusis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 25, 2022
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. She was Founder and Executive Producer of the award-winning future-shaping events series, Creative Innovation Global.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA. Rick Doblin, Ph.D.,
Cannabis Law Report
MARCH 29, 2020
At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. This post explores the manufacturing and research standards to consider when conducting research studies with cannabis. . . Product Quality in Manufacturing.
SMPL
MAY 26, 2020
We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. The company developed a 98 percent CBD drug for the boy and others like him.
Green Relief
MAY 13, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. In 2013, the International Journal of Molecular Science reported on how TBI is affected by diurnal variations of the endocannabinoid system. But CB1 proved to be a tricky target.
Expert insights. Personalized for you.
105 
Let's personalize your content